Sofgen Pharma S.A. (PRCWF) — SEC Filings

Q: What are the key financial highlights for Sofgen Pharma S.A.?

Key financial highlights for Sofgen Pharma S.A. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Sofgen Pharma S.A.?

Key executives at Sofgen Pharma S.A. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Sofgen Pharma S.A. stock?

Risk factors for Sofgen Pharma S.A. (PRCWF) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Sofgen Pharma S.A.?

Forward-looking statements and predictions from Sofgen Pharma S.A. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Sofgen Pharma S.A.. Recent 6-K filing on Dec 5, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Sofgen Pharma S.A. on SEC EDGAR

Overview

Sofgen Pharma S.A. (PRCWF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 20-F filed on Sep 3, 2025: Procaps Group, S.A. (PRCWF) filed its 20-F for the fiscal year ended December 31, 2023, indicating a significant change in its public trading status. The company's Ordinary Shares were delisted from Nasdaq effective February 4, 2025, and are now quoted on the OTC Expert Market under the symbol "PROC

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Sofgen Pharma S.A. is neutral.

Filing Type Overview

Sofgen Pharma S.A. (PRCWF) has filed 34 6-K, 1 20-F, 13 SC 13D/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (48)

6-K Filing — 6-K · Dec 5, 2025
6-K Filing — 6-K · Nov 19, 2025
Procaps Delisted from Nasdaq, Shifts to OTC Expert Market — 20-F · Sep 3, 2025 Risk: high
Procaps Group, S.A. (PRCWF) filed its 20-F for the fiscal year ended December 31, 2023, indicating a significant change in its public trading status. The compan
Procaps Group CEO Departs — 6-K · Aug 1, 2025 Risk: medium
Procaps Group, S.A. announced on July 25, 2025, that Dr. Camilo Camacho has been relieved of his duties as Interim Co-Chief Executive Officer. The company is a
Procaps Group Appoints New Directors to Board and Committees — 6-K · Jul 14, 2025 Risk: low
On July 14, 2025, Procaps Group, S.A. announced the appointment of Mr. Fernando Moreira Muniz and Mr. Carlos Romero to its Board of Directors. These appointment
Procaps Group Appoints Two New Directors to Board — 6-K · May 13, 2025 Risk: low
On May 8, 2025, Procaps Group, S.A. appointed Mr. Carlos Garcia Iragorri and Mr. Manuel Vial as new Directors to its Board. These appointments were made to fill
Procaps Group Announces Private Share Offering — 6-K · Apr 14, 2025 Risk: medium
Procaps Group, S.A. announced on March 24, 2025, that its Board of Directors approved a private offering of its ordinary shares to accredited investors. This of
Procaps Group Raises $130M, Restructures Debt — 6-K · Apr 9, 2025 Risk: medium
On April 9, 2025, Procaps Group, S.A. announced the successful completion of a $130 million capital raise, which included secured convertible notes issued to Ho
Procaps Group Shareholders Approve All Matters at Extraordinary Meeting — 6-K · Mar 25, 2025 Risk: low
Procaps Group, S.A. held an extraordinary general meeting of shareholders on March 24, 2025, where all submitted matters were approved. The company is a foreign
Procaps Group Sets Shareholder Meeting for March 24 — 6-K · Mar 6, 2025 Risk: low
Procaps Group, S.A. announced on March 5, 2025, that its extraordinary general meeting of shareholders will take place on March 24, 2025. Shareholders of record
Procaps Group Schedules Extraordinary Shareholder Meeting — 6-K · Feb 19, 2025 Risk: low
Procaps Group, S.A. announced on February 19, 2025, that an extraordinary general meeting of shareholders will be held on March 7, 2025. The record date for det
Procaps Appoints Interim Co-CEOs Amid CEO Departure — 6-K · Feb 3, 2025 Risk: medium
Procaps Group, S.A. announced on January 29, 2025, the appointment of Ms. Melissa Angelini and Dr. Camilo Camacho as Interim Co-Chief Executive Officers. This c
Procaps Group Director Jose Minski Resigns — 6-K · Jan 21, 2025 Risk: low
Procaps Group, S.A. announced on January 17, 2025, that Jose Minski has resigned as a Director of the Board. His resignation is effective upon the appointment o
Procaps Group Appoints New Director and Audit Committee Member — 6-K · Jan 16, 2025 Risk: low
On January 10, 2025, Procaps Group, S.A. appointed Mr. Jorddy Antonio Pérez to its Board of Directors and as a member of the Audit Committee. Mr. Pérez has also
Procaps Group Faces Nasdaq Delinquency Over Financial Filings — 6-K · Jan 3, 2025 Risk: medium
Procaps Group, S.A. received a delinquency letter from Nasdaq on December 31, 2024, for failing to file its interim financial statements as required by Listing
Procaps Group Appoints Interim CFO for Financial Restatement — 6-K · Dec 31, 2024 Risk: medium
Procaps Group, S.A. announced on December 27, 2024, that its Board of Directors appointed an Interim Chief Financial Officer, effective December 19, 2024. This
Procaps Group Holds Shareholder Meetings — 6-K · Dec 20, 2024 Risk: low
On December 16, 2024, Procaps Group, S.A. held both an extraordinary general meeting and an annual general meeting of shareholders. Shareholders approved and ad
Procaps Group Plans Up to $100M Private Offering — 6-K · Dec 3, 2024 Risk: medium
Procaps Group, S.A. announced on November 27, 2024, that its Board of Directors approved a private offering of up to $100 million in securities. This offering i
Hoche Partners Pharma Updates Procaps Group Stake — SC 13D/A · Dec 3, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 13) to its Schedule 13D on November 29, 2024, regarding its holdings in Procaps Group, S.A. The filin
Procaps Group Schedules Shareholder Meetings for Dec 16 — 6-K · Nov 29, 2024 Risk: low
Procaps Group, S.A. announced on November 29, 2024, that its extraordinary and annual general meetings of shareholders will take place on December 16, 2024, at
Procaps Group Faces Nasdaq Delinquency Over Unfiled 20-F Report — 6-K · Nov 15, 2024 Risk: medium
Procaps Group, S.A. filed a Form 6-K on November 15, 2024, reporting a delinquency letter received from Nasdaq on May 16, 2024. The letter indicated the company
Procaps Group Appoints New Director to Board — 6-K · Nov 1, 2024 Risk: low
On October 28, 2024, Procaps Group, S.A. appointed Roberto Albisetti as a Director to its Board and as a member of the M&A Committee. This appointment is part o
Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake — SC 13D/A · Oct 29, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 12) to its Schedule 13D on October 29, 2024, regarding Procaps Group, S.A. The filing indicates a cha
Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake — SC 13D/A · Oct 28, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 11) to its Schedule 13D on October 28, 2024, regarding its holdings in Procaps Group, S.A. The filing
Procaps Group to Restate Financials After Investigation — 6-K · Oct 10, 2024 Risk: medium
Procaps Group, S.A. announced on October 10, 2024, that it will restate its previously issued financial statements. This decision follows an independent investi
Hoche Partners Pharma Amends Procaps Group Stake — SC 13D/A · Oct 10, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 10) to its Schedule 13D on October 10, 2024, regarding its holdings in Procaps Group, S.A. The filing
Procaps Group Director Resigns — 6-K · Oct 8, 2024 Risk: low
On October 8, 2024, Ruben Minski resigned from the Board of Directors of Procaps Group, S.A. The company is currently evaluating potential successors for his po
Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake — SC 13D/A · Sep 19, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 9) to its Schedule 13D on September 19, 2024, regarding Procaps Group, S.A. The filing indicates a ch
Procaps Group Issues $5M Subordinated Note to Minski Family Entity — 6-K · Sep 18, 2024 Risk: medium
On September 12, 2024, Procaps Group, S.A. issued a $5.0 million junior unsecured subordinated promissory note to Olvi Investment Limited. Olvi Investment Limit
Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake — SC 13D/A · Sep 4, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 8) to its Schedule 13D on September 4, 2024, regarding its holdings in Procaps Group, S.A. The filing
Procaps Group S.A. CEO Outlines Strategic Priorities — 6-K · Sep 3, 2024 Risk: low
On September 3, 2024, Procaps Group, S.A. issued a press release detailing the current state of its business and outlining key strategic priorities. The press r
Procaps Group Secures Forbearance on $195M Debt — 6-K · Aug 26, 2024 Risk: medium
On August 25 and 26, 2024, Procaps Group, S.A. and its subsidiaries entered into forbearance agreements with creditors concerning approximately $195 million in
Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake — SC 13D/A · Aug 23, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 7) to its Schedule 13D on August 23, 2024, regarding its holdings in Procaps Group, S.A. The filing i
Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake — SC 13D/A · Aug 12, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 6) to its Schedule 13D on August 12, 2024, regarding its holdings in Procaps Group, S.A. The filing i
Hoche Partners Amends Procaps Group Stake Filing — SC 13D/A · Aug 8, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 5) to its Schedule 13D on August 8, 2024, regarding its holdings in Procaps Group, S.A. The filing in
Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake — SC 13D/A · Jul 29, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 4) to its Schedule 13D on July 29, 2024, regarding its holdings in Procaps Group, S.A. The filing ind
Hoche Partners Pharma Holding S.A. Amends Procaps Group Stake — SC 13D/A · Jul 22, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an amendment (No. 3) to its Schedule 13D on July 22, 2024, regarding its holdings in Procaps Group, S.A. The filing ind
Procaps Group Updates on Internal Accounting Investigation — 6-K · Jul 10, 2024 Risk: medium
Procaps Group, S.A. filed a 6-K on July 10, 2024, providing an update on its ongoing internal investigation initiated by the Audit Committee. The investigation
Procaps Group Appoints New Chairman of the Board — 6-K · Jun 28, 2024 Risk: low
Procaps Group, S.A. announced on June 28, 2024, that Jose Minski will become the new Chairman of the Board of Directors, effective June 30, 2024. He will succee
Procaps Group Receives Nasdaq Delinquency Notice — 6-K · May 20, 2024 Risk: medium
On May 16, 2024, Procaps Group, S.A. received a delinquency letter from Nasdaq because it had not yet filed its Annual Report on Form 20-F for the year ended De
Procaps Group Delays 2023 20-F Filing — 6-K · May 14, 2024 Risk: medium
Procaps Group, S.A. announced on May 14, 2024, that it will be unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, by the
Procaps Group Delays 2023 Financial Filings — 6-K · May 1, 2024 Risk: medium
Procaps Group, S.A. announced on May 1, 2024, that it is delaying the preparation of its financial statements and the filing of its 20-F for the year ended Dece
Procaps Group Forms Strategic Committee for Value Creation — 6-K · Mar 4, 2024 Risk: low
On March 4, 2024, Procaps Group, S.A. announced the formation of a strategic committee. This committee is tasked with exploring initiatives aimed at creating va
Hoche Partners Amends Procaps Group Stake Disclosure — SC 13D/A · Feb 20, 2024 Risk: medium
Hoche Partners Pharma Holding S.A. filed an Amendment No. 2 to its Schedule 13D/A on February 20, 2024, regarding its ownership of Ordinary Shares in Procaps Gr
Procaps Shareholders Re-Elect Entire Board, Rejecting Revocation Bid — 6-K · Jan 24, 2024
Procaps Group, S.A. held a general meeting of shareholders on January 22, 2024, where they rejected a proposal to revoke all current board members. Instead, sha
Procaps Group: Incorrect Voting Instructions for Jan 22 Shareholder Meeting — 6-K · Jan 16, 2024
Procaps Group, S.A. (NASDAQ: PROCS) issued a 6-K filing on January 16, 2024, to inform shareholders that incorrect online voting instructions were provided for
Hoche Partners Amends Procaps Group Stake Disclosure — SC 13D/A · Jan 12, 2024
Hoche Partners Pharma Holding S.A. filed an amendment to their Schedule 13D on January 12, 2024, regarding their ownership in Procaps Group, S.A. This filing, a
Procaps Group Sets Jan 22 Shareholder Meeting; Jan 5 Record Date — 6-K · Jan 5, 2024
Procaps Group, S.A. announced on January 5, 2024, that a general meeting of shareholders will be held on Friday, January 22, 2024, at 3:00 p.m. Luxembourg time.

Risk Profile

Risk Assessment: Of PRCWF's 42 recent filings, 1 were flagged as high-risk, 27 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

Melissa Angelini
Dr. Camilo Camacho
Mr. Fernando Moreira Muniz
Mr. Carlos Romero
Mr. Carlos Garcia Iragorri
Mr. Manuel Vial
Camilo Camacho
Jose Minski
Jorddy Antonio Pérez
Interim Chief Financial Officer
Roberto Albisetti
Ruben Minski
José Antonio Vieira

Industry Context

Procaps Group operates in the pharmaceutical and healthcare industry, a sector characterized by high R&D investment, stringent regulatory oversight, and intense competition. The industry is driven by innovation in drug development, increasing demand for healthcare services, and evolving market access strategies. Companies like Procaps face challenges in navigating complex global supply chains and adapting to diverse regulatory landscapes across different geographies.

Top Tags

ownership-change (10) · corporate-governance (9) · sec-filing (9) · schedule-13d (9) · amendment (9) · shareholder-meeting (8) · governance (6) · financial-reporting (6) · management-change (5) · board-appointment (4)

Key Numbers

Ordinary Shares outstanding: 112,824,183 — as of December 31, 2023
Warrants outstanding: 23,375,000 — as of December 31, 2023
Nominal value per Ordinary Share: $0.01 — consistent share value
Nasdaq delisting date: February 4, 2025 — significant event for trading status
Business Combination Closing Date: September 29, 2021 — date of key corporate transaction
Capital Raise: $130 million — Total funds secured by Procaps Group, S.A.
Potential Capital Raise: $100 million — Maximum amount Procaps Group intends to raise through the private offering.
Amendment Number: 10 — Indicates this is the tenth update to the filing.
Subordinated Promissory Note: $5.0M — Issued to Olvi Investment Limited on September 12, 2024
Financial Indebtedness: $195 million — Amount subject to forbearance agreements
Nominal Value Per Share: $0.01 — Ordinary Shares of Procaps Group, S.A.

Related Companies

PROCF · PROC

Frequently Asked Questions

What are the latest SEC filings for Sofgen Pharma S.A. (PRCWF)?

Sofgen Pharma S.A. has 48 recent SEC filings from Jan 2024 to Dec 2025, including 34 6-K, 13 SC 13D/A, 1 20-F. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of PRCWF filings?

Across 48 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Sofgen Pharma S.A. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Sofgen Pharma S.A. (PRCWF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Sofgen Pharma S.A.?

Financial highlights for Sofgen Pharma S.A. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for PRCWF?

The investment thesis for PRCWF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Sofgen Pharma S.A.?

Key executives identified across Sofgen Pharma S.A.'s filings include Melissa Angelini, Dr. Camilo Camacho, Mr. Fernando Moreira Muniz, Mr. Carlos Romero, Mr. Carlos Garcia Iragorri and 8 others.

What are the main risk factors for Sofgen Pharma S.A. stock?

Of PRCWF's 42 assessed filings, 1 were flagged high-risk, 27 medium-risk, and 14 low-risk.

What are recent predictions and forward guidance from Sofgen Pharma S.A.?

Forward guidance and predictions for Sofgen Pharma S.A. are extracted from SEC filings as they are enriched.